Target validation via monitoring the pNek1-T141>pYAP-Y407 axis was also shown via WB analysis of the excised tumors [44], and interestingly, the expression of PD-L1 (a target of YAP [52]) was likewise suppressed with J54, with important implications for tumor suppression when using immunocompetent mice or men in a future clinical trial. This evidence concerns the gene YAP1 and neoplasm.